Last reviewed 2026-04-20 · How we verify

PF-01367338

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Fatigue
• Anaemia
• Vomiting
• Constipation
• Alanine aminotransferase increased
• Decreased appetite
• Diarrhoea
• Aspartate aminotransferase increased
• Dysgeusia
• Asthenia
• Abdominal pain

Key clinical trials

• The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (PHASE2)
• Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer (PHASE2)
• Pan Tumor Rollover Study (PHASE2)
• A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
• Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
• Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer (PHASE1, PHASE2)
• A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (PHASE3)
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PF-01367338 CI brief — competitive landscape report
• PF-01367338 updates RSS · CI watch RSS
• pharmaand GmbH portfolio CI